PHASEBIO PHARMA Working Capital

Working Capital of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending June 29, 2021 was $72.3 Million (a 1.17% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital increased by 87.48%
  • Annual Working Capital for 2020 was $25.2 Million (a -64.19% decrease from previous year)
  • Annual Working Capital for 2019 was $70.3 Million (a 21.18% increase from previous year)
  • Annual Working Capital for 2018 was $58.1 Million (a -1608.21% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of PHASEBIO PHARMA

Most recent Working Capitalof PHAS including historical data for past 10 years.

Interactive Chart of Working Capital of PHASEBIO PHARMA

PHASEBIO PHARMA Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $72.33 $71.49
2020 $25.19 $38.58 $45.94 $65.05 $25.19
2019 $70.34 $77.41 $89.15 $50.28 $70.34
2018 $58.05 $17.28 $58.05
2017 $-3.85
2016 $3.04

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.